Royalty pharma plc RPRX 深 沪
已收盘 12-19 16:00:00 美东时间
38.595
+0.165
+0.43%
华盛通- 最 高40.50
- 今 开38.34
- 成交量 220.52万股
- 最 低 37.83
- 昨 收 38.43
- 总市值 167.89亿
- 52周最高 41.24
- 市盈率 静 25.83
- 换手率 0.51%
- 52周最低 25.18
- 委 比 63.41%
- 总股本 4.35亿
- 历史最高 55.14
- 量 比 0.80
- 振 幅 6.95%
- 历史最低 1.10
- 每 手 1
- 风险率 3.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.
12-06 00:49
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Royalty Pharma将参加高盛第46届全球医疗健康大会，并进行网络直播。公司专注于生物制药特许权收购和创新资助，拥有多个知名产品的特许权组合。
06-04 20:15
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
2024-09-19 01:35
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Tuesday, Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago. Results in the quarter were primarily impacted by a negative adjustment to prior periods' estimat...
2024-09-04 21:09
Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement
05:49 PM EDT, 09/03/2024 (MT Newswires) -- Royalty Pharma plc (RPRX) entered into a $150 million capped synthetic royalty funding agreement with an Ascendis Pharma (ASND) unit. The Ascendis Pharma Bone Diseases subsidiary will get an upfront payment of $150 million in exchange for a 3% royalty on US...
2024-09-04 05:49
